No Data
No Data
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $38
Strong Buy Recommendation for TG Therapeutics Driven by Briumvi's Market Potential in RMS Treatment
TG Therapeutics Call Volume Above Normal and Directionally Bullish
TG Therapeutics (NASDAQ:TGTX) Shareholders Have Earned a 36% CAGR Over the Last Five Years
10 Health Care Stocks With Whale Alerts In Today's Session
Are Robust Financials Driving The Recent Rally In TG Therapeutics, Inc.'s (NASDAQ:TGTX) Stock?